Compare NMTC & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMTC | NTRB |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Medical/Dental Instruments | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5M | 42.4M |
| IPO Year | 2010 | N/A |
| Metric | NMTC | NTRB |
|---|---|---|
| Price | $3.71 | $3.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.90 | N/A |
| AVG Volume (30 Days) | ★ 31.0K | 8.0K |
| Earning Date | 05-12-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,097,692.00 | N/A |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | $31.90 | $3,394.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 163.47 | N/A |
| 52 Week Low | $0.55 | $3.40 |
| 52 Week High | $5.40 | $11.68 |
| Indicator | NMTC | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 42.26 |
| Support Level | $0.69 | $3.44 |
| Resistance Level | $4.87 | $4.24 |
| Average True Range (ATR) | 0.37 | 0.18 |
| MACD | -0.21 | -0.02 |
| Stochastic Oscillator | 5.66 | 17.94 |
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.